Hello, everybody. My name is Teresa Amaral, and today I’m here to talk to you about biomarkers. I would like to frame this in relation to the treatment of patients with melanoma, especially early-stage melanoma. Do we have any biomarkers that we could use in the early stage of melanoma?
Of Interest
NCCN Guidelines Update Includes HEPZATO KIT for Uveal Melanoma
Updates to the NCCN guidelines recommend HEPZATO KIT for use in hepatic-dominant uveal melanoma as a Category 2A treatment option.
Lifileucel Approval Paves the Way for Personalized Minimally-Invasive T-Cell Therapies
The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.
New cancer vaccine method boosts potency and scope
Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma.